Project Grant R21AG086855

Award Date 9/15/24
Completion Date 5/31/26
Dollars Obligated $431K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $161,500.00 to investigate the role of perineuronal nets (PNN) in the development of postoperative delirium in aged mice. The research aims to test the hypothesis that changes in PNN and parvalbumin-positive neurons coincide with delirium-like cognitive impairment in aged mice subjected to anesthesia, surgery, and intensive care unit (ICU)-like conditions. The project will also examine whether...
This $2,356,117 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to improve the perioperative management of patients with Alzheimer's disease and related dementias. The primary objectives are to: (1) identify the extent to which surgical patients with these conditions are at increased risk for adverse postoperative outcomes, and (2) estimate the association between various perioperative interventions and the incidence...
The Washington University Office of Sponsored Research Services Division was awarded a $311,000 Project Grant under the National Institute on Aging's Aging Research program (CFDA 93.866) to determine temporal links between changes in circadian rhythms, systemic inflammation, and delirium severity in older adults undergoing elective cardiac surgery. The research aims to establish the clinical relevance of molecular circadian rhythm disruptions during the perioperative period and shift delirium...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a proteomic signature for predicting postoperative delirium and long-term cognitive decline in older cardiac surgery patients. The $1,631,690 award will leverage plasma samples from the ongoing PANDORA trial to: Derive and validate a delirium protein signature using state-of-the-art proteomics (Aim 1). The top 10 proteins will be independently validated across all 450 placebo group...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is focused on advancing the understanding of attentional resilience in older adults, particularly in the context of delirium and Alzheimer's disease. The $3,871,366 award to Duke University, spanning from August 2024 to April 2029, will evaluate the neural mechanisms underlying attentional control and how they contribute to maintaining cognitive function despite...
This federal Project Grant award, totaling $198,355.00, was provided by the National Institute on Aging under the Aging Research grant program (CFDA 93.866) to The Johns Hopkins University. The primary objective is to conduct a Positron Emission Tomography (PET) study to measure changes in neural circuitry associated with affective symptoms (depression, anxiety, irritability, agitation) and cognitive deficits in patients with behavioral variant frontotemporal dementia (bvFTD). The research...
This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $715,801 to Duke University to investigate the causal role of blood-brain barrier dysfunction and neuroinflammation in exacerbating postoperative delirium and subsequent onset of Alzheimer's disease and related dementias in aging and hypertension. The overarching goal is to elucidate how hypertension primes the neurovascular unit and worsens delirium-like behavior after orthopedic...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is focused on investigating the mechanisms underlying neuronal hyperexcitability and sex differences in Alzheimer's disease (AD). The $249,433 award, effective September 15, 2024 through June 30, 2026, will be carried out by the University of Illinois. The project aims to leverage biophysically-informed computational modeling and experimental data from mouse models to better understand the role...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $174,528 to the University of Wisconsin System to establish foundational data on the epidemiology of delirium, the delivery of evidence-based delirium prevention measures, and potential barriers and facilitators to delivering those measures among the rapidly aging incarcerated population. The project aims to improve hospital care for older incarcerated adults by strengthening the...
This $6,226,692 project grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support research to examine the role of neuronal hyperexcitability and proteostasis (protein homeostasis) in the development of Alzheimer's disease (AD). The primary focus is on investigating how modifications in brain activity, particularly in the locus coeruleus (LC) and hippocampus (HPC) regions, can lead to the key pathological hallmarks of AD....

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the "Mitigating Delirium with Fluvoxamine Treatment for Non-Cardiac Surgery (MD FLUNCS): Feasibility Trials & Mechanistic Insights" research project. The $430,850 award will fund a feasibility study to evaluate the use of the antidepressant fluvoxamine as a potential intervention to mitigate the risk of postoperative delirium, which is linked to systemic inflammation, neuroinflammation, and altered synaptic plasticity. The research, led by Washington University in St. Louis, will include a sub-award to the University of Sydney to serve as an enrolling site for the clinical trial. The goal is to establish the biological plausibility and infrastructure for a larger-scale clinical trial to assess fluvoxamine's efficacy in reducing delirium risk and potential progression to Alzheimer's disease and related dementias. The project period runs from Sep 2024 to May 2026.

Generated 8/5/25, 6:04 AM